ESR1 and breast cancer: Previous published LFS BC studies considered ER-positive cut off greater than or equal to 1% (9, 25–27), nevertheless, updated guidelines (28, 29) incorporated the concept of ER-low-positive due to its potential impact in prognosis and predictive role in neoadjuvant chemotherapy response (44).